Search results for "bowel"

showing 10 items of 637 documents

Quantitative patterns of Hsps in tubular adenoma compared with normal and tumor tissues reveal the value of Hsp10 and Hsp60 in early diagnosis of lar…

2016

Large bowel carcinogenesis involves accumulation of genetic alterations leading to transformation of normal mucosa into dysplasia and, lastly, adenocarcinoma. It is pertinent to elucidate the molecular changes occurring in the pre-neoplastic lesions to facilitate early diagnosis and treatment. Heat shock proteins (Hsps), many of which are molecular chaperones, are implicated in carcinogenesis, and their variations with tumor progression encourage their study as biomarkers. There are many reports on Hsps and cancer but none to our knowledge on their systematic quantification in pre-neoplastic lesions of the large bowel. We performed immunohistochemical determinations of Hsp10, Hsp60, Hsp70, …

0301 basic medicineAdenomaMaleDysplasiaPathologymedicine.medical_specialtyColorectal cancerColonLarge bowelChaperoneBiologyAdenocarcinomamedicine.disease_causeBiochemistryMitochondrial Proteins03 medical and health sciencesBiomarker; Chaperone; Dysplasia; Hsps; Large bowel; Tubular adenoma; Biochemistry; Cell Biology0302 clinical medicineTubular adenomaHeat shock proteinmedicineBiomarkers TumorChaperonin 10HspHumansIntestinal MucosaEarly Detection of CancerAgedTubular adenomaAged 80 and overLamina propriaOriginal PaperBiomarkerCell BiologyChaperonin 60Middle Agedmedicine.disease030104 developmental biologymedicine.anatomical_structureDysplasiaTumor progression030220 oncology & carcinogenesisCase-Control StudiesImmunologyAdenocarcinomaFemaleCarcinogenesisColorectal Neoplasms
researchProduct

The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.

2019

BACKGROUND We report a prospective, nationwide cohort evaluating the safety and effectiveness of CT-P13. METHODS A structured database was used to record serious adverse events (SAEs), clinical remission/response, inflammatory biomarkers (CRP and calprotectin), and endoscopic findings. RESULTS Eight hundred ten patients with inflammatory bowel disease (IBD) (452 Crohn's disease [CD]) were enrolled. Four hundred fifty-nine patients were naive to anti-TNFα (group A), 196 had a previous exposure (group B), and the remaining 155 were switched to CT-P13 (group C). All patients were included in the safety evaluation with a mean follow-up of 345 ± 215 days and a total number of 6501 infusions. One…

0301 basic medicineAdultMalemedicine.medical_specialtyAdolescentSettore MED/12 - GASTROENTEROLOGIABiosimilar; Crohn's disease; CT-P13; Inflammatory bowel disease; Inflectra; Infliximab; Remsima; Ulcerative colitis; Adolescent; Adult; Antibodies Monoclonal; Female; Follow-Up Studies; Gastrointestinal Agents; Humans; Inflammatory Bowel Diseases; Infliximab; Italy; Male; Prognosis; Prospective Studies; Young AdultInflectraInflammatory bowel diseaseInflammatory bowel diseaseAntibodies03 medical and health sciencesYoung Adult0302 clinical medicineGastrointestinal AgentsInternal medicineMonoclonalmedicineImmunology and AllergyHumansProspective StudiesRemsimaProspective cohort studyCrohn's diseasebusiness.industryCrohn's disease; ulcerative colitis; inflammatory bowel disease; Infliximab; Remsima; Inflectra; biosimilar; CT-P13BiosimilarSettore MED/09 - MEDICINA INTERNAGastroenterologyAntibodies Monoclonalmedicine.diseaseInflammatory Bowel DiseasesPrognosisUlcerative colitisInfliximabInfliximabCrohn's disease030104 developmental biologyUlcerative colitisItalyCohort030211 gastroenterology & hepatologyFemaleCalprotectinbusinessCT-P13Cohort studymedicine.drugFollow-Up StudiesInflammatory bowel diseases
researchProduct

A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients with Crohn's Di…

2019

Background and aims There is an unmet need to better understand the effectiveness of different biologics in inflammatory bowel diseases. We aimed at performing a multicentre, real-life comparison of the effectiveness of infliximab [IFX] and adalimumab [ADA] in Crohn's disease [CD]. Methods Data of consecutive patients with CD treated with IFX and ADA from January 2013 to May 2017 were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Disease. We used propensity score-matching accounting for the main baseline characteristics in TNF-α inhibitor-naive and non-naive patients. Results A total of 632 patients [735 total treatments] were included. Among naive patients, a cli…

0301 basic medicineAdultMalemedicine.medical_specialtyInflammatory bowel diseaseGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineCrohn DiseaseGastrointestinal AgentsInternal medicinemedicineAdalimumabHumansYoung adultSicilypropensity scoreCrohn's diseasebusiness.industryTumor Necrosis Factor-alphaGastroenterologyAdalimumabGeneral MedicineOdds ratiomedicine.diseaseAdalimumab; infliximab; propensity score; Adalimumab; Adult; Crohn Disease; Female; Gastrointestinal Agents; Humans; Infliximab; Male; Propensity Score; Sicily; Treatment Outcome; Tumor Necrosis Factor-alpha; Young AdultInfliximab030104 developmental biologyTreatment OutcomeCohortPropensity score matching030211 gastroenterology & hepatologyFemalebusinessinfliximabmedicine.drug
researchProduct

Body Mass Index and Associated Clinical Variables in Patients with Non-Celiac Wheat Sensitivity.

2019

Background: Non-Celiac Wheat Sensitivity (NCWS) is still a largely undefined condition, due to the lack of a diagnostic marker. Few data are available about the nutritional characteristics of NCWS patients at diagnosis. Aims: To evaluate the proportion of NCWS patients who were underweight, normal weight, overweight, or obese at diagnosis, and to search for possible correlations between their Body Mass Index (BMI) and other NCWS-related disease characteristics. Patients and Methods: The clinical charts of 145 NCWS patients (125 F, 20 M, mean age 37.1 &plusmn

0301 basic medicineAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaClinical variablesHLA haplotypelcsh:TX341-641autoimmune diseaseAutoimmunityDiseaseWheat HypersensitivityOverweightBody Mass Index (BMI)GastroenterologyArticleBody Mass IndexCeliac Disease (CD)03 medical and health sciencesIrritable Bowel Syndrome (IBS)0302 clinical medicineThinnessWeight lossInternal medicineHLA-DQ AntigensmedicineHumansIn patientautoimmune diseasesIrritable bowel syndromeRetrospective StudiesNutrition and Dieteticsbusiness.industrynutritional and metabolic diseasesMiddle AgedOverweightmedicine.diseasePrognosis030104 developmental biologyHaplotypesnon-celiac wheat sensitivity (NCWS)030211 gastroenterology & hepatologyFemalemedicine.symptomUnderweightbusinesslcsh:Nutrition. Foods and food supplyBody mass indexFood ScienceNutrients
researchProduct

Dual Role of Endogenous Serotonin in 2,4,6-Trinitrobenzene Sulfonic Acid-Induced Colitis.

2016

Background and Aims: Changes in gut serotonin content have been described in Inflammatory Bowel Disease and in different experimental models of colitis: the critical role of this monoamine in the pathogenesis of chronic gastrointestinal inflammation is gradually emerging. Aim of the present study was to evaluate the contribution of endogenous serotonin through the activation of its specific receptor subtypes to the local and systemic inflammatory responses in an experimental model of Inflammatory Bowel Disease. Methods: Colitis was induced by intrarectal 2,4,6-TriNitroBenzene Sulfonic acid in mice subacutely treated with selective antagonists of 5-HT1A (WAY100135), 5-HT2A (Ketanserin), 5-HT…

0301 basic medicineAgonistmedicine.medical_specialtyKetanserinmedicine.drug_classInflammationBiology5-HT2A receptorInflammatory bowel diseaseProinflammatory cytokine03 medical and health sciences0302 clinical medicineInternal medicinemedicinePharmacology (medical)5-HT1A receptorColitisReceptorintestineOriginal ResearchPharmacologylcsh:RM1-950apoptosismedicine.disease030104 developmental biologyEndocrinologylcsh:Therapeutics. Pharmacologyinflammation030211 gastroenterology & hepatologySerotoninmedicine.symptommedicine.drugFrontiers in pharmacology
researchProduct

Subclinical gut inflammation in ankylosing spondylitis

2015

Purpose of review Subclinical gut inflammation has been described in a significant proportion of patients with ankylosing spondylitis (AS), up to 10% of them developing it during the time of clinically overt inflammatory bowel disease. Histologic, immunologic, and intestinal microbiota alterations characterize the AS gut. Recent findings Microbial dysbiosis as well as alterations of innate immune responses have been demonstrated in the gut of AS. Furthermore, a growing body of evidence suggests that the gut of AS patients may be actively involved in the pathogenesis of AS through the production of proinflammatory cytokines, such as IL-23p19, and the differentiation of potentially pathogenic…

0301 basic medicineAnkylosing spondylitis; Gut inflammation; Innate lymphoid cells; Interleukin-17; Interleukin-23; Adaptive Immunity; Animals; Cytokines; Disease Models Animal; Dysbiosis; Gastrointestinal Microbiome; Humans; Immunity Innate; Inflammation; Inflammatory Bowel Diseases; Intestines; Macrophages; Mice; Spondylitis Ankylosing; Rheumatology; Medicine (all)MacrophageAdaptive ImmunityInterleukin-23Inflammatory bowel diseaseGastroenterologyMiceInterleukin 23InnateMedicineSubclinical infectionMedicine (all)Interleukin-17digestive oral and skin physiologyInnate lymphoid cellIntestineIntestinesCytokinesmedicine.symptomHumanAnkylosingmedicine.medical_specialtyDisease ModelInflammationdigestive system03 medical and health sciencesRheumatologyInternal medicineInnate lymphoid cellAnimalsHumansSpondylitis AnkylosingCytokineSpondylitisGut inflammationSpondylitiInflammationAnkylosing spondylitisAnimalbusiness.industryMacrophagesInflammatory Bowel DiseaseImmunityInflammatory Bowel Diseasesmedicine.diseaseImmunity InnateDysbiosiGastrointestinal MicrobiomeAnkylosing spondylitiDisease Models Animal030104 developmental biologyDysbiosisbusinessDysbiosisCurrent Opinion in Rheumatology
researchProduct

AphaMax®, an Aphanizomenon Flos-Aquae Aqueous Extract, Exerts Intestinal Protective Effects in Experimental Colitis in Rats

2020

Background: Aphanizomenon flos-aquae (AFA) is a unicellular cyanobacterium considered to be a &ldquo

0301 basic medicineAntioxidantmedicine.medical_treatmentInflammationlcsh:TX341-641Pharmacologymedicine.disease_causeInflammatory bowel disease03 medical and health sciences0302 clinical medicineImmune systeminflammatory bowel diseasemedicineColitisblue-green algaechemistry.chemical_classificationReactive oxygen speciesNutrition and DieteticsbiologyAphanizomenon flos-aquaemedicine.disease030104 developmental biologychemistryinflammation030220 oncology & carcinogenesisMyeloperoxidasebiology.proteinmedicine.symptomlcsh:Nutrition. Foods and food supplyOxidative stressFood ScienceNutrients
researchProduct

Mast cells crosstalk with B cells in the gut and sustain IgA response in the inflamed intestine.

2021

B lymphocytes are among the cell types whose effector functions are modulated by mast cells (MCs). The B/MC crosstalk emerged in several pathological settings, notably the colon of inflammatory bowel disease (IBD) patients is a privileged site in which MCs and IgA+ cells physically interact. Herein, by inducing conditional depletion of MCs in red MC and basophil (RMB) mice, we show that MCs control B cell distribution in the gut and IgA serum levels. Moreover, in dextran sulfate sodium (DSS)-treated RMB mice, the presence of MCs is fundamental for the enlargement of the IgA+ population in the bowel and the increase of systemic IgA production. Since both conventional B-2 and peritoneal-deriv…

0301 basic medicineCell typeColon[SDV]Life Sciences [q-bio]ImmunologyPopulationInflammationBasophilBiologySettore MED/08 - Anatomia Patologicabehavioral disciplines and activitiesInflammatory bowel diseasecell-to-cell interplay colitis IgAinnate-like B cells mast cells03 medical and health sciencesMice0302 clinical medicinemedicineImmunology and AllergyAnimalsMast CellsColitisIntestinal MucosaeducationB cellComputingMilieux_MISCELLANEOUSInflammationeducation.field_of_studyB-LymphocytesTumor Necrosis Factor-alphaDextran Sulfatemedicine.diseaseColitisInflammatory Bowel DiseaseshumanitiesInnate-like B cellsGastrointestinal MicrobiomeImmunoglobulin AMice Inbred C57BLCrosstalk (biology)030104 developmental biologymedicine.anatomical_structureCell-to-cell interplayCell-to-cell interplay; Colitis; IgA; Innate-like B cells; Mast cellsImmunologymedicine.symptomIgA030215 immunologyEuropean journal of immunologyReferences
researchProduct

The activation of Wnt signaling by a STAT6-dependent macrophage phenotype promotes mucosal repair in murine IBD

2016

The complete repair of the mucosa constitutes a key goal in inflammatory bowel disease (IBD) treatment. The Wnt signaling pathway mediates mucosal repair and M2 macrophages that coordinate efficient healing have been related to Wnt ligand expression. Signal transducer and activator of transcription 6 (STAT6) mediates M2 polarization in vitro and we hypothesize that a STAT6-dependent macrophage phenotype mediates mucosal repair in acute murine colitis by activating the Wnt signaling pathway. Our results reveal an impaired mucosal expression of M2 macrophage-associated genes and delayed wound healing in STAT6(-/-) mice treated with 2,4,6-trinitrobenzenesulfonic acid (TNBS). These mice also ex…

0301 basic medicineCellular differentiationImmunologyBiology03 medical and health sciencesMice0302 clinical medicineImmunology and AllergyAnimalsHumansIntestinal MucosaCells CulturedSTAT6Mice KnockoutMice Inbred BALB CWound HealingWnt signaling pathwayLGR5LRP5Cell DifferentiationColitisInflammatory Bowel DiseasesCell biologyWnt Proteins030104 developmental biologyPhenotypeTrinitrobenzenesulfonic AcidImmunologySTAT proteinMacrophages PeritonealSignal transductionWound healingSTAT6 Transcription Factor030215 immunologySignal Transduction
researchProduct

Gut-CNS-Axis as Possibility to Modulate Inflammatory Disease Activity-Implications for Multiple Sclerosis.

2017

In the last decade the role of environmental factors as modulators of disease activity and progression has received increasing attention. In contrast to classical environmental modulators such as exposure to sun-light or fine dust pollution, nutrition is an ideal tool for a personalized human intervention. Various studies demonstrate a key role of dietary factors in autoimmune diseases including Inflammatory Bowel Disease (IBD), rheumatoid arthritis or inflammatory central nervous system (CNS) diseases such as Multiple Sclerosis (MS). In this review we discuss the connection between diet and inflammatory processes via the gut–CNS-axis. This axis describes a bi-directional communication syst…

0301 basic medicineCentral Nervous SystemMultiple SclerosisCentral nervous systemInflammationReviewBiologyInflammatory bowel diseaseModels BiologicalCatalysisInorganic ChemistryDisease activitylcsh:Chemistry03 medical and health sciencesImmune systemmedicinemicrobiotaAnimalsHumansPhysical and Theoretical ChemistryMolecular Biologylcsh:QH301-705.5SpectroscopyInflammationMultiple sclerosisOrganic ChemistryGeneral Medicinemedicine.diseaseComputer Science ApplicationsGastrointestinal Tractgut–CNS-axisimmune system030104 developmental biologymedicine.anatomical_structurenutritionlcsh:Biology (General)lcsh:QD1-999Rheumatoid arthritisAdjunctive treatmentImmunologymedicine.symptomInternational journal of molecular sciences
researchProduct